- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Diagnosis and Prevalence of Demodex Blepharitis
Neda Shamie, MD, summarizes the prevalence and clinical manifestations of Demodex Blepharitis.
EP: 1.Overview of Demodex Blepharitis
EP: 2.Pathophysiology of Demodex Blepharitis
EP: 3.Diagnosing Demodex Blepharitis in Clinical Practice
EP: 4.Differential Diagnosis: Key Features of Demodex Blepharitis
EP: 5.Risk Factors and Mental Health Impact of Demodex Blepharitis
EP: 6.Treatment of Demodex Blepharitis
EP: 7.Diagnosis and Prevalence of Demodex Blepharitis
EP: 8.Exploring a Recently Approved Therapy for Demodex
EP: 9.Payer Approval + Alternate Treatments for Demodex Blepharitis
EP: 10.Outlook on the Future of Demodex Blepharitis Treatment
EP: 11.Understanding Demodex Blepharitis Pathogenesis
EP: 12.Cost-Effective Medication Access in Demodex Blepharitis Treatment
EP: 13.Other Clinical Considerations in Demodex Blepharitis Treatment
This is a video synopsis/summary of an Insights involving Neda Shamie, MD.
Until recently, there were no FDA-approved therapies for Demodex blepharitis. In the past, Demodexblepharitis was quite common but often left untreated for years. Various abrasive in-office procedures, home therapies encouraging patients to abrade their own eyelashes/eyelids, and chemical cleansers were tried to lessen the Demodexload, but none treated the root cause. These approaches often irritated patients more than the actual disease.
Demodexblepharitis is highly prevalent, with a recent study finding that 56% of cataract patients had pathognomonic signs, even without symptoms. Over 90% of patients intolerant of contact lenses and 60% of those on dry eye treatment had Demodex, indicating it is an underdiagnosed condition.
Diagnosing Demodexblepharitis is simple. The eye care specialist uses a slit lamp to look at the patient’s eyelash line. When the patient looks down, the doctor examines the eyelash base for collarettes, which are mite excretions that cluster and cake on the lashes. This can cause inflammation, hair follicle loss, and other issues.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
